Literature DB >> 11258406

Prognostic value of 201Tl myocardial scintigraphy after coronary artery bypass grafting.

L Sarda1, L Fuchs, R Lebtahi, M Faraggi, N Delahaye, U Hvass, D Le Guludec.   

Abstract

BACKGROUND: 201Tl myocardial scintigraphy (201Tl SPECT) is of strong prognostic value in various populations with suspected or known coronary artery disease. However, its value in patients with coronary artery bypass grafting (CABG) is not fully assessed.
METHODS: We examined 115 consecutive patients to determine the relation between clinical data/stress 201Tl SPECT performed 5+/-3 years after CABG, and subsequent cardiac events.
RESULTS: Thirteen patients (11%) had stress-induced angina, 22 (19%) had electrical positivity, and 97 (84%) had abnormal scintigraphy, including 62 (54%) with reversible defects. During follow-up (35+/-22 months), there were nine cardiac deaths, seven myocardial infarctions, and 20 revascularization procedures. Multivariate Cox analysis identified the delay between CABG and scintigraphy (P<0.01, relative risk (RR) = 1.01), the extent of stress 201Tl defects (P = 0.04, RR = 1.18), and increased stress 201Tl lung uptake (P = 0.03, RR = 3.56) as significant predictors of cardiac deaths/infarctions. Delay between CABG and scintigraphy (P < 0.001, RR = 1.01), the extent of stress 201Tl defects (P = 0.03, RR = 1.15), and that of reversible defects (P = 0.05, RR = 1.13) were the only significant predictors of total events.
CONCLUSIONS: Besides the delay between CABG and scintigraphy, the scintigraphic parameters were the only significant and additive predictors of cardiac events in 115 patients with CABG.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11258406     DOI: 10.1097/00006231-200102000-00011

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  Is a revision of the "nuclear cardiology warranty" in order?

Authors:  Gregory S Thomas; Michael I Miyamoto
Journal:  J Nucl Cardiol       Date:  2003 May-Jun       Impact factor: 5.952

2.  Long-term prognostic value of early poststress (99m)Tc-tetrofosmin lung uptake during exercise (SPECT) myocardial perfusion imaging.

Authors:  Panagiotis Georgoulias; Ioannis Tsougos; Varvara Valotassiou; Chara Tzavara; Petros Xaplanteris; Nikolaos Demakopoulos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-17       Impact factor: 9.236

3.  Dipyridamole stress echocardiography stratifies outcomes of asymptomatic patients with recent myocardial revascularization.

Authors:  Andrea Rossi; Tiziano Moccetti; Francesco Faletra; Paolo Cattaneo; Mariagrazia Rossi; Elena Pasotti; Cecilia Fantoni; Claudio Anzà; Massimo Baravelli
Journal:  Int J Cardiovasc Imaging       Date:  2007-12-22       Impact factor: 2.357

4.  Prognostic value of dobutamine stress echocardiography in patients with previous coronary revascularisation.

Authors:  M Bountioukos; A Elhendy; R T van Domburg; A F L Schinkel; J J Bax; B J Krenning; E Biagini; V Rizzello; M L Simoons; D Poldermans
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

Review 5.  Non-invasive Ischaemia Testing in Patients With Prior Coronary Artery Bypass Graft Surgery: Technical Challenges, Limitations, and Future Directions.

Authors:  Andreas Seraphim; Kristopher D Knott; Joao B Augusto; Katia Menacho; Sara Tyebally; Benjamin Dowsing; Sanjeev Bhattacharyya; Leon J Menezes; Daniel A Jones; Rakesh Uppal; James C Moon; Charlotte Manisty
Journal:  Front Cardiovasc Med       Date:  2021-12-23

6.  Evaluation of graft patency by computed tomographic angiography in symptom-free post-coronary artery bypass surgery patients.

Authors:  Dhakshinamurthy Vijay Anand; Eric Lim; David Lipkin; Avijit Lahiri
Journal:  J Nucl Cardiol       Date:  2008-03-06       Impact factor: 3.872

Review 7.  Myocardial perfusion scintigraphy: the evidence.

Authors:  S R Underwood; C Anagnostopoulos; M Cerqueira; P J Ell; E J Flint; M Harbinson; A D Kelion; A Al-Mohammad; E M Prvulovich; L J Shaw; A C Tweddel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.